Press Releases

Fox Rothschild Advises Hemostasis in Combination with Everis Medical

Share on:

Fox Rothschild advised Hemostasis, LLC, an innovator in advanced sinus dressings and surgical hemostats, in its combination with Everis Medical, a medical device company specializing in Otolaryngology, Head & Neck Surgery and adjacent surgical specialties.

Backed by Shore Capital Partners, the combined company will operate as Everis Medical, with Hemostasis’ technologies and team becoming a core part of the organization.

The Fox team was led by Phillip B. Martin and included Sarah M. Rozek, Anitra Varhadkar and Meghan Currie.

The transaction brings together two companies of comparable scale and combines Everis’ Otolaryngology/Head & Neck portfolio with Hemostasis’ chitosan-based sinus dressing and hemostat platform.

Together, the companies will offer a comprehensive portfolio for sinus and nasal surgery spanning repair and reconstruction, hemostasis, post-operative healing and infection management.

“Coming together with Everis is a true joining of two companies that share the same ambition,” said Michael Spearman, Co-Founder and Chairman of Hemostasis, LLC. “As part of Everis, our technologies will reach more surgeons and more patients, faster, and together we will continue advancing the technology in sinus dressings.”

Terms of the deal were not disclosed.

Learn more.


As this article contains statements regarding past performance, please note that results may vary depending on your particular facts and legal circumstances.